Clinical Trial Update: Compare Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in EEC [Phase 2]

View source ↗

Summary

Phase 2 study by Anergis comparing dose regimens of AllerT in adults with birch pollen–induced allergic rhino-conjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• AllerT

Snippet

Sponsor: Anergis | Conditions: Allergic Rhino-Conjunctivitis | Phase 2 | Status: COMPLETED